Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
Welcome,         Profile    Billing    Logout  
 26 Trials 
64 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Powderly, John Mellors; William
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 MAb) Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
PT199, Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer
08/25
09/25
NCT05388435: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Terminated
1/2
17
US
SKL27969
SK Life Science, Inc.
Advanced Solid Tumor
03/24
03/24
NCT04875806: A Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors

Terminated
1/2
40
US
NC762
NextCure, Inc.
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
01/24
01/24
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
07/25
KEYNOTE-B59, NCT04977453: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
GI-101, Pembrolizumab (KEYTRUDA®), KEYTRUDA®, Lenvatinib, Lenvima®, Local Radiotherapy, GI-101A
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma, Microsatellite Stable Colorectal Carcinoma, Merkel Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
10/25
10/26
XTX101-01, NCT04896697: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting
1/2
136
US
vilastobart (XTX101), Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
NCT05055609: Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Recruiting
1
85
US
TRE-515
Trethera
Solid Tumor, Adult, Oncology
12/26
06/27
NCT05118841: Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Recruiting
1
60
US
ZX-4081
Nanjing Zenshine Pharmaceuticals
Advanced Solid Tumor
05/23
05/24
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
NCT04417465: First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Active, not recruiting
1
101
Europe, Japan, US, RoW
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumors Cancer
05/26
05/26
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
PEEL-224-001, NCT05329103: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Recruiting
1
42
US
PEEL-224
Peel Therapeutics Inc
Advanced Solid Tumor
03/25
03/26
NCT05569057: A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Recruiting
1
100
US
SIM1811-03, SIM0235, TNFR2 monoclonal antibody
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
06/24
03/25
NCT05571969: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Recruiting
1
40
US
2X-121 and dovitinib
Allarity Therapeutics, Amarex Clinical Research
Advanced Solid Tumors
10/24
12/24
NCT05115292: A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

Active, not recruiting
1
85
US
BJ-005
BJ Bioscience, Inc.
Advanced Solid Tumor or Lymphoma
10/24
10/25
CUE-102-01, NCT05360680: A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Active, not recruiting
1
52
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
12/24
12/26
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT05674526: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Recruiting
1
30
US
WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion, Cetuximab - Cohort Expansion
Wugen, Inc.
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
09/25
06/26
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/25
11/25
NCT06014658: Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting
1
90
US
Antibody-Drug Conjugate
MBrace Therapeutics
Cancer
07/25
11/25
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
NCT05989724: A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Recruiting
1
150
US
SON-DP
Qurgen Inc.
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
09/25
03/26
NCT00571389: A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Recruiting
N/A
1000
US
BioCytics, Inc.
Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
02/25
02/25
Ramos, Juan Carlos
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT02737046: Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Active, not recruiting
2
15
US
Belinostat, PXD101, Beleodaq®, Zidovudine, AZT, Interferon-Alfa-2b, IFN-α-2b, Pegylated Interferon-Alfa-2b, PEG-IFN-α-2b
University of Miami
Adult T-cell Leukemia-Lymphoma, ATLL
07/24
07/25
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Active, not recruiting
2
23
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
12/25
06/26
NCT04305691: Trial of Ixazomib for Kaposi Sarcoma

Recruiting
2
41
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma, Skin
05/25
05/26
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Active, not recruiting
2
314
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
12/24
Imagine-1, NCT04713475 / 2020-001109-22: Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Active, not recruiting
1/2
26
Europe, Canada, US, RoW
PBGM01
Passage Bio, Inc.
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
02/26
02/29
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Active, not recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
NCT05321940: Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Withdrawn
1
18
NA
STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, STING (Stimulator of Interferon Genes)-Dependent Activators, STAVs-Loaded Autologous Leukemic Cells, STING-dependent innate immune agonists, Dendritic Cell Vaccine, DC Vaccine
Juan C. Ramos, MD
Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Adult T-Cell Leukemia/Lymphoma
11/25
11/26
OR-ARI-EAP-NPC, NCT04316637: Early Access Program With Arimoclomol in US Patients With NPC

Available
N/A
US
Arimoclomol
ZevraDenmark
Niemann-Pick Disease, Type C
 
 
E²-RADIatE, NCT03818503: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
N/A
2000
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Cancer
04/26
04/26
PETIFI, NCT05688592: Usefulness of PET-CT for Invasive Fungal Infection

Recruiting
N/A
224
Europe
PET-CT, Before-and-after study
Puerta de Hierro University Hospital, Gilead Sciences
Invasive Fungal Infections
10/24
12/24
VRAM, NCT03221244: Virtual Reality Attention Management

Recruiting
N/A
50
US
VR Treatment, VR Active Control
University of California, Davis, National Institute of Mental Health (NIMH)
ADHD
09/26
07/27
Sue, Yuh-Mou
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Calendar Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease
Recruiting
3
2000
Europe, Canada, RoW
Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo
The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
06/27
12/27
REGEN-006, NCT05099770: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Recruiting
3
685
Europe, Canada, US, RoW
Renal Autologous Cell Therapy (REACT), Sham Comparator
Prokidney, Iqvia Pty Ltd, PPD
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
02/27
02/27
Wu, Mai-Szu
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

Completed
3
141
RoW
Ferric citrate, Placebo
Panion & BF Biotech Inc.
Anemia of Chronic Kidney Disease
10/22
12/22
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
REGEN-006, NCT05099770: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Recruiting
3
685
Europe, Canada, US, RoW
Renal Autologous Cell Therapy (REACT), Sham Comparator
Prokidney, Iqvia Pty Ltd, PPD
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
02/27
02/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT02933827: Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease

Completed
1/2
39
RoW
ELIXCYTE
UnicoCell Biomed CO. LTD, Protech Pharmaservices Corporation (PPC)
Moderate to Severe Chronic Kidney Disease
04/19
06/23
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting
1
16
Europe, Japan, US, RoW
Mezagitamab, TAK-079
Takeda
Kidney Disease, Glomerulonephritis
03/26
03/26
Camps, Isabel Ruiz
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Roemmich, Jill
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Active, not recruiting
1
160
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
12/24
05/25
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/25
11/25
Lu, Po-Liang
RAPID, NCT05979545: EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

Recruiting
4
1900
RoW
Rapid Diagnostics, BioFire FilmArray BCID2, BioFire FilmArray Pneumonia Plus Panel, BioFire FilmArray Pneumonia Panel
National University of Singapore, Pfizer, Biomerieux inc
Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection, Hospital-acquired Pneumonia
10/26
12/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT06069141: Comparisons of Treatment Responses of Early Syphilis to Benzathine Penicillin G With or Without Doxycycline

Recruiting
N/A
688
RoW
Benzathine Penicillin G, Doxycycline Capsule
National Taiwan University Hospital, National Taiwan University Hospital Hsin-Chu Branch, Far Eastern Memorial Hospital, Taipei Veterans General Hospital, Taiwan, Taoyuan General Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung Veterans General Hospital.
Early Syphilis, Latent, Serological Relapse After Treatment
12/25
12/26
Liu, Yung-Ching
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
Kao, Chin-Chin
REGEN-006, NCT05099770: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Recruiting
3
685
Europe, Canada, US, RoW
Renal Autologous Cell Therapy (REACT), Sham Comparator
Prokidney, Iqvia Pty Ltd, PPD
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
02/27
02/27
Hsu, Yu-Juei
REGEN-006, NCT05099770: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Recruiting
3
685
Europe, Canada, US, RoW
Renal Autologous Cell Therapy (REACT), Sham Comparator
Prokidney, Iqvia Pty Ltd, PPD
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
02/27
02/27
Li, Yu-Hsuan
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/25
11/25

Download Options